Tech Company Financing Transactions
Dyne Therapeutics Funding Round
Dyne Therapeutics, based in Waltham, secured $50 million in funding from Atlas Venture, Forbion Capital Partners and MPM Capital.
Transaction Overview
Company Name
Announced On
4/4/2019
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
830 Winter St.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Dyne Therapeutics (Nasdaq: DYN) was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Brumm
Chief Operating Officer
Susanna High
Chief Scientific Officer
Romesh Subramanian
Vice President
John Davis
Vice President
Molly White
Vice President
Daniel Wilson
VP - Administration
Rick Scalzo
VP - Bus. Development
Jonathan McNeill
VP - Bus. Development
Chris Mix
VP - Finance
Gene Kim
VP - Manufacturing
John Najim
VP - R & D
Oxana Beskrovnaya
VP - R & D
Mo Qatanani
VP - Regulatory Affairs
Debra Feldman
Browse more venture capital transactions:
Prev: 4/3/2019: Sqreen venture capital transaction
Next: 4/4/2019: SurveySparrow venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs